FX06 operates as an endothelium-protective drug and may prevent detrimental host inflammatory responses including endotheliitis, hyperinflammation, and hypercytokinemia (better known as cytokine storm). Strikingly, it does not rely on host-virus interactions and thus acts independently of any viral mutations. FX06 does not manipulate the host metabolism or immune system and is in general well tolerated. The COVend Project aims to develop a FX06 precision therapy for the clinical management ARDS of different etiology, focusing on the prevention of disease progression to severe illness. The main objective is to test the therapeutic candidate FX06 in a placebo-controlled, double-blind, randomised, multi-national phase II clinical trial. The COVend project brings together clinicians, biochemists, data scientists, and economists to gain a comprehensive understanding of ARDS and identify effective treatment strategies for real-world scenarios. IXION2.0 is being conducted in five European countries (France, Germany, Lithuania, Romania and Spain) and is open to patients of all genders and all ethnicities, ensuring a diverse study population representative for all European citizens.The main project goals include preparing and distributing the investigational medicinal product (IMP), conducting the clinical trial, investigating the molecular profile of COVID-19 and its change upon FX06 treatment, creating additional solid evidence based on sophisticated in vitro studies with endothelial cell lines, developing biomarkers and open source decision support applications for an FX06 precision therapy, and evaluating the health-economic benefits and cost-effectiveness of this therapy. Based on the scientific knowledge gained in COVend and IXION2.0 we aim to aid patients with ARDS related to COVID-19 or other aetiologies , and contribute to a society that is prepared for future disease outbreaks.